Get started
Author

Gertjan van Hal

Observed names: G. Van Hal, G. van Hal, Gertjan VAN HAL, Gertjan Van Hal
ORCID: 0009-0005-6322-5762
Observed ORCID: 0009-0005-6322-5762
OpenAlex ID: A5044825175
LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)
2022 · M.P. Goetz, M. Toi, et al. · Annals of Oncology · 96
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C β-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer
2007 · Jeany M. Rademaker-Lakhai, Laurens V. Beerepoot, et al. · Clinical Cancer Research · 52
Abstract GS01-12: MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer
2024 · Matthew Goetz, Masakazu Toi, et al. · Cancer Research · 17
Abstract PD13-11: PD13-11 Final Overall Survival Analysis of Monarch 2 : A Phase 3 trial of Abemaciclib Plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
2023 · Antonio Llombart-Cussac, George Sledge, et al. · Cancer Research · 15
Abemaciclib plus fulvestrant in East Asian women with HR +, HER2 − advanced breast cancer: Overall survival from MONARCH 2
2022 · Masakazu Toi, Chiun‐Sheng Huang, et al. · Cancer Science · 11
PDF
An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer
2022 · Elgene Lim, Frances Boyle, et al. · Breast Cancer Research and Treatment · 8
PDF
Phase I and pharmacologic study of enzastaurin HCl, gemcitabine and cisplatin
2004 · J. M. Rademaker-Lakhai, L. Beereport, et al. · Journal of Clinical Oncology · 8
Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
2010 · C. Haioun, F. Morschhauser, et al. · Journal of Clinical Oncology · 6
Abemaciclib Plus Fulvestrant in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Final Overall Survival Results From MONARCH 2
2025 · Patrick Neven, Masakazu Toi, et al. · JCO oncology advances. · 2
Final Overall Survival Analysis of MONARCH 2: A Phase 3 Trial of Abemaciclib plus Fulvestrant in Patients with Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer
2023 · E.-M. Grischke, A. Llombart-Cussac, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie · 2
A phase 1/2 trial of tersolisib (LY4064809/STX-478), a pan-mutant-selective PI3Kα inhibitor (PI3Kαi), in PIK3CA -mutant advanced solid tumors: Updated results from PIKALO-1.
2026 · Komal L. Jhaveri, Alberto J. Montero, et al. · Journal of Clinical Oncology · 1
A randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in participants with relapsed or refractory Ewing sarcoma.
2023 · Gertjan VAN HAL, Alba Rubio-San-Simón, et al. · Journal of Clinical Oncology · 1
Abstract P5-14-05: The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study
2020 · Elgene Lim, Frances Boyle, et al. · Cancer Research · 1
A Randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in patients with relapsed or refractory Ewing sarcoma
2026 · Alba Rubio-San-Simon, Marilena Cesari, et al. · EJC Paediatric Oncology
PDF
Abstract P1-18-21: Abemaciclib plus fulvestrant or nonsteroidal aromatase inhibitor in participants with HR+, HER2- breast cancer - A pooled analysis of the endocrine therapy-naïve participants with measurable disease in MONARCH 2 and MONARCH 3
2022 · Matthew P. Goetz, Jose Luis Gonzalez Trujillo, et al. · Cancer Research
241P Abemaciclib plus fulvestrant in participants with HR+/HER2- advanced breast cancer: A pooled analysis of the endocrine therapy naïve (EN) participants in MONARCH 2
2021 · J. Luis-Gonzalez Trujillo, M. Escobar Gomez, et al. · Annals of Oncology
PDF
Works count: 16
Citation count: 220
H-index: 7
I10-index: 5
Year
Topic
Type